IN VITRO BIOGENIC AMINE TRANSPORTER TESTING FOR POTENTIA

Project: Research project

Description

The National Institute on Drug Abuse (NIDA), Medications Development
Division (MDD) has established a Cocaine Treatment Discovery Program
(CTDP) to accelerate the identification of potential medications for the
medical management of cocaine dependence. This program involves testing
compounds through a decision-based screening scheme designed to identify
potential treatment agents which will either antagonize the effects of
cocaine or substitute for cocaine. The purpose of this contract is to determine the affinity of up to 600
test compounds at biogenic amine transporter (dopamine, serotonin, and
norepinephrine) binding sites. In addition, up to 500 of these compounds
will be assessed for their ability to inhibit the reuptake of biogenic
amines and up to 200 of them will be evaluated for their ability to
facilitate an "amphetamine-like" release of biogenic amines. Compounds will, in general, be submitted by NIDA to the contractor "blind"
with a coded identification number and information about the compound such
as their physical properties and solubility. CTDP data generated from this
contract on proprietary compounds will be maintained in confidence by NIDA
for three (3) years from the date of reporting of each test result to the
compound submitter. After three (3) years, NIDA will disclose this
information into the public domain through its MDD structure-activity
database. Compound submitters are free to disclose CTDP data generated on
their compounds prior to the three (3) year period of non-disclosure. The contractor will meet annually with NIDA and consultants with expertise
in in vitro biogenic amine transporter assays to review the quality of the
contract data and discuss new state-of-the-art technologies and
methodologies for potential incorporation into the contract.
StatusFinished
Effective start/end date9/30/934/30/97

Funding

  • National Institutes of Health
  • National Institutes of Health: $356,613.00
  • National Institutes of Health
  • National Institutes of Health: $175,814.00

Fingerprint

National Institute on Drug Abuse (U.S.)
Biogenic Amines
Cocaine
Aptitude
Contracts
Cocaine-Related Disorders
Serotonin Plasma Membrane Transport Proteins
Dopamine Plasma Membrane Transport Proteins
Public Sector
Amphetamine
Therapeutics
Consultants
Solubility
Binding Sites
Technology
In Vitro Techniques

ASJC

  • Medicine(all)